| scholarly article | Q13442814 |
| P50 | author | Colin S Brown | Q54965054 |
| Andy Borman | Q67488441 | ||
| P2093 | author name string | Silke Schelenz | |
| Elizabeth M Johnson | |||
| Katie Jeffery | |||
| Surabhi K Taori | |||
| Anna Jeffery-Smith | |||
| Rohini Manuel | |||
| Candida auris Incident Management Team | |||
| P2860 | cites work | Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America | Q28272494 |
| Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia | Q28818814 | ||
| Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species | Q28829671 | ||
| Multidrug-resistant Candida auris: 'new kid on the block' in hospital-associated infections? | Q30245326 | ||
| Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China | Q30398438 | ||
| Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts | Q30561825 | ||
| Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the rapid identification of yeasts causing bloodstream infections | Q30888780 | ||
| Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital | Q33401940 | ||
| Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. | Q33609053 | ||
| Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally | Q33704302 | ||
| Current perspective on emergence, diagnosis and drug resistance in Candida auris | Q33812143 | ||
| First three reported cases of nosocomial fungemia caused by Candida auris | Q34196357 | ||
| New clonal strain of Candida auris, Delhi, India | Q34372060 | ||
| Draft Genome Sequence of a Fluconazole-Resistant Candida auris Strain from a Candidemia Patient in India | Q34485537 | ||
| Non-albicans Candida Infection: An Emerging Threat | Q34488096 | ||
| Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris | Q34492906 | ||
| Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America | Q34505582 | ||
| First hospital outbreak of the globally emerging Candida auris in a European hospital | Q34543358 | ||
| Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses | Q34547546 | ||
| Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek | Q35586995 | ||
| Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. | Q35835357 | ||
| Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature | Q35959484 | ||
| Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods | Q36022880 | ||
| Identification and typing of the emerging pathogen Candida auris by matrix-assisted laser desorption ionisation time of flight mass spectrometry | Q36049838 | ||
| Identification of Uncommon Candida Species Using Commercial Identification Systems | Q36155872 | ||
| Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) for rapid identification of micro-organisms in the routine clinical microbiology laboratory | Q36227115 | ||
| Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel | Q37664411 | ||
| British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases | Q38378032 | ||
| Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Healthcare Surface | Q38659451 | ||
| Drug development challenges and strategies to address emerging and resistant fungal pathogens | Q38798805 | ||
| Candida auris candidaemia in Indian ICUs: analysis of risk factors | Q38883902 | ||
| The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. | Q38949297 | ||
| Identification of Candida haemulonii Complex Species: Use of ClinProTools(TM) to Overcome Limitations of the Bruker Biotyper(TM), VITEK MS(TM) IVD, and VITEK MS(TM) RUO Databases | Q39033046 | ||
| In vitro efficacy of disinfectants utilised for skin decolonization and environmental decontamination during a hospital outbreak with Candida auris. | Q39092094 | ||
| Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. | Q39092102 | ||
| Donor-derived transmission of Candida auris during lung transplantation | Q39092106 | ||
| Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. | Q39092125 | ||
| Effectiveness of Disinfectants Against Candida auris and Other Candida Species | Q39092133 | ||
| First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia | Q39092138 | ||
| Incidence, characteristics and outcome of ICU-acquired candidemia in India | Q39092143 | ||
| Multidrug-resistant endemic clonal strain of Candida auris in India. | Q39092162 | ||
| In Vitro Interactions of Echinocandins with Triazoles Against Multidrug-Resistant Candida auris | Q39092177 | ||
| Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris | Q39092215 | ||
| Simple low cost differentiation of Candida auris from Candida haemulonii complex using CHROMagar Candida medium supplemented with Pal's medium | Q39092219 | ||
| Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis | Q39092224 | ||
| Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection | Q39092240 | ||
| The yeasticidal activity of chemical disinfectants and antiseptics against Candida auris. | Q39092268 | ||
| Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species | Q39092300 | ||
| Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. | Q39092317 | ||
| Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation | Q39092330 | ||
| Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. | Q39092336 | ||
| Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities - United States, June 2016-May 2017. | Q39092357 | ||
| Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016. | Q39092367 | ||
| Molecular identification and classification of Trichophyton mentagrophytes complex strains isolated from humans and selected animal species | Q41509098 | ||
| Can Multidrug-Resistant Candida auris Be Reliably Identified in Clinical Microbiology Laboratories? | Q42326663 | ||
| Candida auris-associated candidemia, South Africa | Q42712931 | ||
| Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses | Q42741161 | ||
| Candida auris candidemia in Kuwait, 2014. | Q42787996 | ||
| Candidemia caused by amphotericin B and fluconazole resistant Candida auris | Q44304263 | ||
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. | Q47643534 | ||
| In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole. | Q50950336 | ||
| Candida urinary tract infections--treatment | Q51175452 | ||
| Candida auris for the clinical microbiology laboratory: Not your grandfather's Candida species. | Q53704744 | ||
| In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. | Q53789385 | ||
| First reported case of multidrug-resistant Candida auris in Canada. | Q55017741 | ||
| First report of Candida auris in Oman: Clinical and microbiological description of five candidemia cases | Q88232114 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Candida auris | Q26816853 |
| P577 | publication date | 2017-11-15 | |
| P1433 | published in | Clinical Microbiology Reviews | Q5133777 |
| P1476 | title | Candida auris: a Review of the Literature | |
| P478 | volume | 31 |
| Q92011714 | A Decade of Antifungal Leads from Natural Products: 2010-2019 |
| Q57461265 | A Novel Actin Binding Drug with Efficacy |
| Q58111377 | Adhesins of Yeasts: Protein Structure and Interactions |
| Q90618019 | Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus |
| Q92339644 | Candida auris Isolates of the Southern Asian and South African Lineages Exhibit Different Phenotypic and Antifungal Susceptibility Profiles In Vitro |
| Q92927244 | Candida auris in Germany and Previous Exposure to Foreign Healthcare |
| Q58550566 | Candida auris in South Africa, 2012-2016 |
| Q98170039 | Candida auris in the UK: Introduction, dissemination, and control |
| Q89510130 | Candida auris, an Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind? |
| Q51149128 | Candida auris, what do paediatricians need to know? |
| Q53690366 | Candida auris: Disinfectants and Implications for Infection Control. |
| Q54242269 | Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. |
| Q91704984 | Candida tropicalis is the most prevalent yeast species causing candidemia in Algeria: the urgent need for antifungal stewardship and infection control measures |
| Q50117670 | Candida-Epithelial Interactions |
| Q64076653 | Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait |
| Q64064934 | Clinical spectrum and factors impacting outcome of Candida auris: a single center study from Pakistan |
| Q90405276 | Crystal structure and transient dimerization for the FKBP12 protein from the pathogenic fungus Candida auris |
| Q92543621 | Does Online Search Behavior Coincide with Candida auris Cases? An Exploratory Study |
| Q92915825 | Draft Genome Sequence of Candida auris Strain LOM, a Human Clinical Isolate from Greater Metropolitan Houston, Texas |
| Q92707855 | Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis |
| Q92082086 | Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens |
| Q92812046 | Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016-20171 |
| Q58598193 | Epidemiology, clinical characteristics, resistance, and treatment of infections by |
| Q114115328 | Eradication of Fungi Using MoSe2/Chitosan Nanosheets |
| Q90574312 | External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris |
| Q59804393 | Filamentation in Candida auris, an emerging fungal pathogen of humans: passage through the mammalian body induces a heritable phenotypic switch |
| Q110951300 | From environmental adaptation to host survival: Attributes that mediate pathogenicity of Candida auris |
| Q49679927 | Gaining Insights from Candida Biofilm Heterogeneity: One Size Does Not Fit All. |
| Q51782762 | Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. |
| Q57793431 | Hog1 Regulates Stress Tolerance and Virulence in the Emerging Fungal Pathogen Candida auris |
| Q89986135 | Human inborn errors of immunity underlying superficial or invasive candidiasis |
| Q64226654 | Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS |
| Q92237024 | Identification and antifungal susceptibility profiles of Kodamaea ohmeri based on a seven-year multicenter surveillance study |
| Q93088245 | Identification of Drug Resistant Candida auris |
| Q92932769 | Improved efficacy of antifungal drugs in combination with monoterpene phenols against Candida auris |
| Q90573021 | In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism |
| Q104135019 | In vitro synergy of isavuconazole in combination with colistin against Candida auris |
| Q52598778 | Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait. |
| Q64130194 | Insights into the Unique Nature of the East Asian Clade of the Emerging Pathogenic Yeast Candida auris |
| Q89855313 | Invasive Candida bovina Infection, France |
| Q64242716 | Investigating Antifungal Susceptibility in Species With MALDI-TOF MS-Based Assays |
| Q90280509 | Isolation of Candida auris from Ear of Otherwise Healthy Patient, Austria, 2018 |
| Q92142505 | Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019 |
| Q90146452 | Isolation of Candida auris from invasive and non-invasive samples of a patient suffering from vascular disease, Italy, July 2019 |
| Q92752608 | Molecular Diagnostics in the Times of Surveillance for Candida auris |
| Q92666321 | Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen |
| Q64061044 | Multi-omics characterization of the necrotrophic mycoparasite Saccharomycopsis schoenii |
| Q98830964 | Nanotechnological strategies for systemic microbial infections treatment: A review |
| Q94464436 | Nine Things Genomics Can Tell Us About Candida auris |
| Q91623044 | Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for In Vitro Eradication of Candida auris Biofilm |
| Q91715567 | On the Origins of a Species: What Might Explain the Rise of Candida auris? |
| Q98930173 | Origin of new emergent Coronavirus and Candida fungal diseases—Terrestrial or cosmic? |
| Q58609308 | Rapid Detection of ERG11-Associated Azole Resistance and FKS-Associated Echinocandin Resistance in Candida auris. |
| Q90291132 | Rapid and extensive karyotype diversification in haploid clinical Candida auris isolates |
| Q93166142 | Something wicked this way comes: What health care providers need to know about Candida auris |
| Q61806029 | Sugar Sensing and Signaling in and |
| Q91529794 | The Fungal Histone Acetyl Transferase Gcn5 Controls Virulence of the Human Pathogen Candida albicans through Multiple Pathways |
| Q57296241 | The mycoparasitic yeast Saccharomycopsis schoenii predates and kills multi-drug resistant Candida auris |
| Q55689919 | Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance. |
| Q64089898 | Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Species From 1997-2016 |
| Q90706869 | [Candida auris: estrategias y retos para prevenir un brote] |
Search more.